All‐cause mortality (7 months) · participants with diagnosed DVT
Oral DTIs showed no clear difference in all‐cause mortality (7 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality · atrial fibrillation patients with CKD
Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with a pulmonary embolism, confirmed by standard imaging techniques
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · children with or without anaemia at baseline
Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
RR 1.05 [0.52, 2.11]
728 participants
Low
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality (3 to 6 months) · participants with diagnosed DVT
Oral factor Xa inhibitors showed no clear difference in all‐cause mortality (3 to 6 months) compared with conventional anticoagulation (moderate certainty).
1 finding from 1 review
All‐cause mortality during hospital stay · preterm or low birth weight infants with PDA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis on the left side of the heart (on native or prosthetic valves) with bacteraemia for Streptococcus, Enterococcus…
It is very uncertain whether partial oral treatment changes all‐cause mortality during hospital stay and all‐cause mortality at… compared with conventional intravenous treatment of endocarditis on the left side… (very low certainty).
1 finding from 1 review
All‐cause mortality at final · people with moderate to severe oral paraquat poisoning
Glucocorticoid with cyclophosphamide plus usual care may leads to lower all‐cause mortality at final compared with usual care (with or without placebo) (low certainty).
2 findings from 1 review
Short‐term all‐cause mortality · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial leads to lower short‐term all‐cause mortality compared with transfemoral approach (high certainty).
1 finding from 1 review
All‐cause mortality Advanced haemodynamic monitoring · patients with proximal femoral fracture
It is very uncertain whether advanced haemodynamic monitoring changes all‐cause mortality Advanced haemodynamic monitoring compared with protocol using standard measures such (very low certainty).
1 finding from 1 review
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review